Lantheus Holdings, Inc. $LNTH Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 407,529 shares of the medical equipment provider’s stock after selling 48,326 shares during the quarter. Epoch Investment Partners Inc. owned about 0.61% of Lantheus worth $27,121,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. increased its stake in Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares during the period. Farther Finance Advisors LLC increased its stake in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the period. Resona Asset Management Co. Ltd. increased its stake in Lantheus by 35.7% in the fourth quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 292 shares during the period. Finally, Parallel Advisors LLC increased its stake in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LNTH shares. William Blair restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Jefferies Financial Group reiterated a “buy” rating and set a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Price Performance

LNTH stock opened at $104.52 on Monday. The company has a market cap of $6.81 billion, a P/E ratio of 25.19 and a beta of -0.03. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $104.57. The company’s 50-day moving average price is $90.68 and its 200 day moving average price is $76.78. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.